Literature DB >> 17486339

Metabolic imaging using PET.

Takashi Kudo1.   

Abstract

INTRODUCTION: There is growing evidence that myocardial metabolism plays a key role not only in ischaemic heart disease but also in a variety of diseases which involve myocardium globally, such as heart failure and diabetes mellitus. Understanding myocardial metabolism in such diseases helps to elucidate the pathophysiology and assists in making therapeutic decisions. MEASUREMENT: As well as providing information on regional changes, PET can deliver quantitative information about both regional and global changes in metabolism. This capability of quantitative measurement is one of the major advantages of PET along with physiological positron tracers, especially relevant in evaluating diseases which involve the whole myocardium. DISCUSSION: This review discusses major PET tracers for metabolic imaging and their clinical applications and contributions to research regarding ischaemic heart disease and other diseases such as heart failure and diabetic heart disease. Future applications of positron metabolic tracers for the detection of vulnerable plaque are also highlighted briefly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486339     DOI: 10.1007/s00259-007-0440-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  98 in total

1.  Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease.

Authors:  David A Morrow; Michael M Givertz
Journal:  Circulation       Date:  2005-11-22       Impact factor: 29.690

2.  Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability.

Authors:  R W Burt; O W Perkins; B E Oppenheim; D S Schauwecker; L Stein; H N Wellman; R M Witt
Journal:  J Nucl Med       Date:  1995-02       Impact factor: 10.057

3.  Delineation of myocardial oxygen utilization with carbon-11-labeled acetate.

Authors:  M Brown; D R Marshall; B E Sobel; S R Bergmann
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

4.  Human adipose tissue glucose uptake determined using [(18)F]-fluoro-deoxy-glucose ([(18)F]FDG) and PET in combination with microdialysis.

Authors:  K A Virtanen; P Peltoniemi; P Marjamäki; M Asola; L Strindberg; R Parkkola; R Huupponen; J Knuuti; P Lönnroth; P Nuutila
Journal:  Diabetologia       Date:  2001-12       Impact factor: 10.122

5.  Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.

Authors:  Gary D Lopaschuk
Journal:  Semin Cardiothorac Vasc Anesth       Date:  2006-09

6.  Validation of an evaluation routine for left ventricular volumes, ejection fraction and wall motion from gated cardiac FDG PET: a comparison with cardiac magnetic resonance imaging.

Authors:  Wolfgang M Schaefer; Claudia S A Lipke; Bernd Nowak; Hans Juergen Kaiser; Arno Buecker; Gabriele A Krombach; Udalrich Buell; Harald P Kühl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-15       Impact factor: 9.236

7.  Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: head-to-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction.

Authors:  Jeroen J Bax; Farzin Fath-Ordoubadi; Eric Boersma; William Wijns; Paolo G Camici
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-04-10       Impact factor: 9.236

8.  Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy.

Authors:  R S Beanlands; D S Bach; R Raylman; W F Armstrong; V Wilson; M Montieth; C K Moore; E Bates; M Schwaiger
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

9.  Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

Authors:  Leong Lee; Ross Campbell; Michaela Scheuermann-Freestone; Rachel Taylor; Prasad Gunaruwan; Lynne Williams; Houman Ashrafian; John Horowitz; Alan G Fraser; Kieran Clarke; Michael Frenneaux
Journal:  Circulation       Date:  2005-11-22       Impact factor: 29.690

10.  Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Barbara Sposato; Giuseppe Mercuro; Massimo Fini
Journal:  Cardiovasc Diabetol       Date:  2003-11-28       Impact factor: 9.951

View more
  5 in total

1.  Enhanced definition PET for cardiac imaging.

Authors:  Ludovic Le Meunier; Piotr J Slomka; Damini Dey; Amit Ramesh; Louis E J Thomson; Sean W Hayes; John D Friedman; Victor Cheng; Guido Germano; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2010-02-12       Impact factor: 5.952

Review 2.  Metabolic Imaging in Humans.

Authors:  Taylor L Fuss; Leo L Cheng
Journal:  Top Magn Reson Imaging       Date:  2016-10

3.  Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation.

Authors:  Kooresh I Shoghi; Robert J Gropler; Terry Sharp; Pilar Herrero; Nicole Fettig; Yi Su; Mayurranjan S Mitra; Attila Kovacs; Brian N Finck; Michael J Welch
Journal:  J Nucl Med       Date:  2008-07-16       Impact factor: 10.057

Review 4.  Quantitative cardiac positron emission tomography: the time is coming!

Authors:  Roberto Sciagrà
Journal:  Scientifica (Cairo)       Date:  2012-08-27

Review 5.  PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts.

Authors:  Victoria R Pell; Friedrich Baark; Filipa Mota; James E Clark; Richard Southworth
Journal:  Curr Cardiovasc Imaging Rep       Date:  2018-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.